why choose us

Course: US Insurer Spending on Ivermectin Prescriptions for COVID-19

CME Credits: 1.00

Released: 2022-01-13

Ivermectin dispensing surged in the US in December 2020, even though evidence suggests ivermectin is ineffective for COVID-19., Studies have not assessed the degree to which insurers cover the costs of ivermectin prescriptions for COVID-19 or estimated wasteful US insurer spending on these prescriptions. We addressed these gaps by using national claims data from December 1, 2020, through March 31, 2021.


Educational Objective
To identify the key insights or developments described in this article


View Full Course